• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Progyny Adds Distinguished Healthcare Executive Elizabeth Bierbower to Board of Directors

    5/29/25 9:03:40 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care
    Get the next $PGNY alert in real time by email

    NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced the addition of healthcare veteran Elizabeth Bierbower to its Board of Directors.

    "As we continue to round out our board's experience, Elizabeth's extensive leadership with some of the largest health plans and deep financial expertise will be invaluable as we scale and innovate across the women's health and family building spectrum," said Pete Anevski, CEO of Progyny. "Her insights will support our strategy to deliver even more value to our members, clients, and shareholders as we expand our reach and impact."

    Bierbower brings more than 30 years of experience in the healthcare industry, having held leadership roles across health plans, provider services, and care innovation. She most recently served as Chairman and CEO of Friday Health Plans and held various senior positions at Humana, including Segment President, President of the Employer Group Segment, and Chief Operating Officer of the Specialty Benefits division. Prior to Humana, she held leadership roles at Highmark Blue Cross Blue Shield and Coventry Health Care.

    Bierbower's depth of healthcare experience also includes serving on the board of directors of numerous companies including Option Care Health, the largest national independent provider for infusion therapy, as well as the boards of several privately held companies, including BlueSprig, Quest Analytics, Paradigm Corp., and Point32Health.

    "Progyny is setting the standard for what comprehensive, outcomes-based women's health and family building benefits should look like in today's workforce," said Bierbower. "I'm joining the board at an exciting time as the company continues its expansion of both products and reach, and I look forward to contributing to the team's objective of advancing access to high-quality care for women and families."

    For more information about Progyny and its Board of Directors, please visit www.progyny.com.

    About Progyny

    Progyny (NASDAQ:PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients, and physicians.

    Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.

    Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit www.progyny.com.

    For Further Information, Please Contact:

    Investors:

    James Hart

    [email protected]

    Media:

    Alexis Ford

    [email protected]



    Primary Logo

    Get the next $PGNY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PGNY

    DatePrice TargetRatingAnalyst
    12/2/2024$17.00Overweight → Neutral
    Analyst
    11/13/2024$26.00 → $19.00Buy → Hold
    Truist
    9/19/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/7/2024$37.00 → $24.00Buy → Hold
    Canaccord Genuity
    8/7/2024$31.00 → $25.00Outperform → Market Perform
    Leerink Partners
    8/7/2024Buy → Neutral
    BTIG Research
    7/16/2024$36.00Mkt Outperform
    JMP Securities
    5/10/2024Overweight → Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $PGNY
    SEC Filings

    See more
    • SEC Form 144 filed by Progyny Inc.

      144 - Progyny, Inc. (0001551306) (Subject)

      6/3/25 12:05:25 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Progyny, Inc. (0001551306) (Filer)

      5/28/25 4:37:32 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 10-Q filed by Progyny Inc.

      10-Q - Progyny, Inc. (0001551306) (Filer)

      5/9/25 4:31:42 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Scott Cheryl sold $59,037 worth of shares (2,675 units at $22.07), decreasing direct ownership by 16% to 14,112 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      6/12/25 5:07:13 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • EVP, GC Swartz Allison covered exercise/tax liability with 339 shares, decreasing direct ownership by 0.41% to 82,095 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      6/5/25 5:23:09 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • CHIEF FINANCIAL OFFICER Livingston Mark S. covered exercise/tax liability with 339 shares, decreasing direct ownership by 0.47% to 72,172 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      6/5/25 5:18:40 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Progyny downgraded by Analyst with a new price target

      Analyst downgraded Progyny from Overweight to Neutral and set a new price target of $17.00

      12/2/24 10:07:08 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny downgraded by Truist with a new price target

      Truist downgraded Progyny from Buy to Hold and set a new price target of $19.00 from $26.00 previously

      11/13/24 8:20:07 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny downgraded by JMP Securities

      JMP Securities downgraded Progyny from Mkt Outperform to Mkt Perform

      9/19/24 7:51:03 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Leadership Updates

    Live Leadership Updates

    See more
    • Progyny Appoints Two Renowned Women's Health Experts to Medical Advisory Board

      NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced the appointment of Morehouse School of Medicine's Regional Dean for Seattle and Puget Sound's Dr. Gloria Richard-Davis – a double-board certified physician in Obstetrics and Gynecology and Reproductive Endocrinology and Infertility, a fellow of the American College of Obstetricians & Gynecologists (FACOG), and a Menopause Society Certified Practitioner (MSCP) – and Columbia University's Dr. Whitney Booker – a double-board certified physician in Obstetrics and Gynecology and Maternal-Fetal Medicine – to its Medical Advisory Board. "As Pr

      5/14/25 9:05:48 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny Names Healthcare Veterans Melissa Cummings as Chief Operating Officer and Geoffrey Clapp as Chief Product Officer

      NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Progyny (NASDAQ:PGNY), a global leader in women's health and family building, today announced the appointments of Melissa Cummings as the company's first Chief Operating Officer (COO) and Geoffrey Clapp as its first Chief Product Officer (CPO). The additions to the executive leadership team will extend Progyny's ability to further drive operational excellence, advance innovation in product design and member experience, and continue to address care gaps and unmet needs across the spectrum of family building and women's health – from preconception to fertility and menopause. "Progyny has established itself at the forefront of building and del

      4/17/25 9:36:59 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Bruker Appoints Laura Francis to its Board of Directors

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

      2/21/25 8:00:00 AM ET
      $BRKR
      $PGNY
      $SIBN
      $SWAV
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Misc Health and Biotechnology Services
      Health Care